Photo of Laura C. Collins,  MBBS

Laura C. Collins, MBBS

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center


lcollins@bidmc.harvard.edu

Laura C. Collins, MBBS

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Pathology, Harvard Medical School
  • Associate Director, Pathology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Collins’ research, teaching and clinical activities have focused primarily on diseases of the breast. The contributions made in these areas have resulted in her recognition locally, nationally and internationally as a leader in the area of breast pathology.

Dr. Collins has been involved in studies that have helped to elucidate prognostic factors in patients with small breast cancers and risk factors for local recurrence in patients with ductal carcinoma in situ (DCIS) of the breast treated with excision alone. She was the lead author on the first study to report on interobserver agreement in the diagnoses rendered on breast core needle biopsies. She collaborated with Nurses’ Health Study investigators to help define the natural history of DCIS by studying the outcome of women with DCIS treated by diagnostic biopsy alone. In ongoing collaborations with the Nurses’ Health Study investigators, Dr. Collins is involved in the evaluation of benign breast disease and breast cancer risk, and in particular she has studied the influence of a positive family history of breast cancer on risk in women with biopsy-confirmed benign breast disease and she has evaluated the magnitude and laterality of subsequent breast cancer risk in women with atypical hyperplasias of the breast. Dr. Collins is the lead pathologist on an epidemiologic-pathologic study of 3,200 women with breast cancer that is using tissue microarrays as a platform to evaluate a variety biomarkers. The goal is to relate breast cancer risk factors to biomarker expression, to relate biomarker expression to outcome, and to assess biomarkers as possible therapeutic targets. Additionally, she serves as a reference pathologist on a multi-institutional study evaluating risk factors for recurrence in almost 1000 women with DCIS treated with breast conserving therapy and she is the principal pathologist for a study evaluating breast cancer and survivorship in young women coordinated through the Dana Farber Cancer Institute.

 

Publications

Powered by Harvard Catalyst
  • Zhang X, Eliassen AH, Tamimi RM, Hazra A, Beck AH, Brown M, Collins LC, Rosner B, Hankinson SE. Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status. Cancer Epidemiol Biomarkers Prev 2015. PubMed
  • Calhoun BC, Collins LC. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting. Semin Diagn Pathol 2015. PubMed
  • Su X, Boeke CE, Collins LC, Baer HJ, Willett WC, Schnitt SJ, Connolly JL, Rosner B, Colditz GA, Tamimi RM. Intakes of fat and micronutrients between ages 13 and 18 years and the incidence of proliferative benign breast disease. Cancer Causes Control 2015; 26:79-90. PubMed
  • Houssami N, Abraham LA, Onega T, Collins LC, Sprague BL, Hill DA, Miglioretti DL. Accuracy of screening mammography in women with a history of lobular carcinoma in situ or atypical hyperplasia of the breast. Breast Cancer Res Treat 2014; 145:765-73. PubMed
  • Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, Connolly JL, Chen WY, Willett WC, Tamimi RM. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. Journal of the National Cancer Institute 2013; 105:1571-8. PubMed
  • Collins LC, Achacoso N, Haque R, Nekhlyudov L, Fletcher SW, Quesenberry CP, Schnitt SJ, Habel LA. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat 2013. PubMed
  • Aroner SA, Collins LC, Connolly JL, Colditz GA, Schnitt SJ, Rosner BA, Hankinson SE, Tamimi RM. Radial scars and subsequent breast cancer risk: results from the Nurses' Health Studies. Breast Cancer Res Treat 2013. PubMed
  • Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE. Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. PLoS ONE 2013; 8:e64225. PubMed
  • Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, Beck AH. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res 2014; 15:R68. PubMed
  • Kaplan JS, Schnitt SJ, Collins LC, Wang Y, Garber JE, Montgomery K, West RB, Krag K, Fetten K, Lincoln A, Tung NM. Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers. Am J Surg Pathol 2012; 36:1483-8. PubMed
  • Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 2012; 30:3468-77. PubMed
  • Su X, Colditz GA, Collins LC, Baer HJ, Sampson LA, Willett WC, Berkey CS, Schnitt SJ, Connolly JL, Rosner BA, Tamimi RM. Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease. Breast Cancer Res Treat 2012; 134:783-91. PubMed
  • Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA, Tamimi RM. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011; 17:1867-74. PubMed
  • Liu Y, Tamimi RM, Collins LC, Schnitt SJ, Gilmore HL, Connolly JL, Colditz GA. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. Breast Cancer Res Treat 2011. PubMed
  • Tamimi RM, Colditz GA, Wang Y, Collins LC, Hu R, Rosner B, Irie HY, Connolly JL, Schnitt SJ. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat 2011. PubMed
  • Alexander BM, Sprott K, Farrow DA, Wang X, D'Andrea AD, Schnitt SJ, Collins LC, Weaver DT, Garber JE. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res 2010; 16:5796-804. PubMed
  • Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szasz AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver D, Garber JE, Richardson AL. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010; 12:R95. PubMed
  • Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2010. PubMed
  • Su X, Tamimi RM, Collins LC, Baer HJ, Cho E, Sampson L, Willett WC, Schnitt SJ, Connolly JL, Rosner BA, Colditz GA. Intake of fiber and nuts during adolescence and incidence of proliferative benign breast disease. Cancer Causes Control 2010; 21:1033-46. PubMed
  • Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast. Am J Surg Pathol 2010; 34:896-900. PubMed
  • Haque R, Achacoso NS, Fletcher SW, Nekhlyudov L, Collins LC, Schnitt SJ, Quesenberry CP, Habel LA. Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care 2010; 16:351-60. PubMed
  • Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010; 12:R12. PubMed
  • Marotti JD, Collins LC, Hu R, Tamimi RM. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2010; 23:197-204. PubMed
  • Aroner SA, Collins LC, Schnitt SJ, Connolly JL, Colditz GA, Tamimi RM. Columnar cell lesions and subsequent breast cancer risk: a nested case-control study. Breast Cancer Res 2010; 12:R61. PubMed
  • Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, Pollak MN, Rosner B, Tamimi RM. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer 2009; 126:180-90. PubMed
  • Collins LC, Achacoso N, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP, Puligandla B, Alshak NS, Goldstein LC, Gown AM, Schnitt SJ, Habel LA. Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol 2009; 33:1802-8. PubMed
  • Collins LC,Wang Y,Connolly JL,Baer HJ,Hu R,Schnitt SJ,Colditz GA,Tamimi RM. Potential Role of Tissue Microarrays for the Study of Biomarker Expression in Benign Breast Disease and Normal Breast Tissue. Appl Immunohistochem Mol Morphol 2009; 17:438-41. PubMed
  • Collins LC,Martyniak AJ,Kandel MJ,Stadler ZK,Masciari S,Miron A,Richardson AL,Schnitt SJ,Garber JE. Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers. Am J Surg Pathol 2010; 33:1093-7. PubMed
  • Nekhlyudov L,Habel LA,Achacoso NS,Jung I,Haque R,Collins LC,Schnitt SJ,Quesenberry CP Jr,Fletcher SW. Adherence to Long-Term Surveillance Mammography Among Women With Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery. J Clin Oncol 2009; 27:3211-6. PubMed
  • Johnson NB, Collins LC. Update on percutaneous needle biopsy of nonmalignant breast lesions. Adv Anat Pathol 2009; 16:183-95. PubMed
  • Baer HJ,Collins LC,Connolly JL,Colditz GA,Schnitt SJ,Tamimi RM. Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies. Cancer 2009; 115:1404-11. PubMed
  • Hilson JB,Schnitt SJ,Collins LC. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. Am J Surg Pathol 2008; 33:227-32. PubMed
  • Habel LA, Achacoso NS, Haque R, Nekhlyudov L, Fletcher SW, Schnitt SJ, Collins LC, Geiger AM, Puligandla B, Acton L, Quesenberry CP. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res 2010; 11:R85. PubMed
  • Kleer CG,Bloushtain-Qimron N,Chen YH,Carrasco D,Hu M,Yao J,Kraeft SK,Collins LC,Sabel MS,Argani P,Gelman R,Schnitt SJ,Krop IE,Polyak K. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res 2008; 14:5357-67. PubMed
  • Shen W, Westgard E, Huang L, Ward MD, Osborn JL, Chau NH, Collins L, Marcum B, Koach MA, Bibbs J, Semmes OJ, Kerry JA. Nuclear trafficking of the human cytomegalovirus pp71 (ppUL82) tegument protein. Virology 2008; 376:42-52. PubMed
  • Strecher VJ, McClure JB, Alexander GL, Chakraborty B, Nair VN, Konkel JM, Greene SM, Collins LM, Carlier CC, Wiese CJ, Little RJ, Pomerleau CS, Pomerleau OF. Web-based smoking-cessation programs: results of a randomized trial. Am J Prev Med 2008; 34:373-81. PubMed
  • Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst 2008; 100:218-21. PubMed
  • Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2007; 409:581-9. PubMed
  • Tamimi RM,Baer HJ,Marotti J,Galan M,Galaburda L,Fu Y,Deitz AC,Connolly JL,Schnitt SJ,Colditz GA,Collins LC. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008; 10:R67. PubMed
  • Collins LC, Schnitt SJ. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology 2008; 52:20-9. PubMed
  • Collins LC, Achacoso NA, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP Jr, Alshak NS, Puligandla B, Brodsky GL, Schnitt SJ, Habel LA. Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol 2007; 20:1149-55. PubMed
  • Tumber A, Collins LS, Petersen KD, Thougaard A, Christiansen SJ, Dejligbjerg M, Jensen PB, Sehested M, Ritchie JW. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 2006; 60:275-83. PubMed
  • Alexander BM, Bryan B, Collins LC, Recht A. Atypical cytology in a persistent seroma following mastectomy for breast cancer: a case report and review of the literature. Breast J 2007; 13:196-9. PubMed
  • Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer 2006; 109:180-7. PubMed
  • Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study. Cancer 2006; 107:1240-7. PubMed
  • Collins LC, Carlo VP, Hwang H, Barry TS, Gown AM, Schnitt SJ. Intracystic Papillary Carcinomas of the Breast: A Reevaluation Using a Panel of Myoepithelial Cell Markers. Am J Surg Pathol 2006; 30:1002-1007. PubMed
  • Upalakalin JN, Collins LC, Tawa N, Parangi S. Carcinoid tumors in the breast. Am J Surg 2006; 191:799-805. PubMed
  • Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006; 19:617-21. PubMed
  • O'Malley FP, Mohsin SK, Badve S, Bose S, Collins LC, Ennis M, Kleer CG, Pinder SE, Schnitt SJ. Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. Mod Pathol 2006; 19:172-9. PubMed
  • Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer 2005; 103:1778-84. PubMed
  • Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol 2005; 18:615-20. PubMed
  • Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14:1082-9. PubMed
  • Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 2005; 123:16-20. PubMed
  • Collins LC, Connolly JL, Page DL, Goulart RA, Pisano ED, Fajardo LL, Berg WA, Caudry DJ, McNeil BJ, Schnitt SJ. Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. Am J Surg Pathol 2004; 28:126-31. PubMed
  • Collins LC, Niloff J, Burke L, Abu-Jawdeh G, Wang H. Relative risk of high grade squamous intraepithelial lesion associated with prior abnormal Pap smears. J Reprod Med 2001; 46:105-9. PubMed
  • Hetelekidis S, Collins L, Silver B, Manola J, Gelman R, Cooper A, Lester S, Lyons JA, Harris JR, Schnitt SJ. Predictors of local recurrence following excision alone for ductal carcinoma in situ. Cancer 1999; 85:427-31. PubMed
  • Abner AL, Collins L, Peiro G, Recht A, Come S, Shulman LN, Silver B, Nixon A, Harris JR, Schnitt SJ, Connolly JL. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer 1999; 83:2502-8. PubMed
Hide